Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
- Author:
Takeshi CHIDA
1
;
Kazuhito KAWATA
;
Kazuyoshi OHTA
;
Erika MATSUNAGA
;
Jun ITO
;
Shin SHIMOYAMA
;
Satoru YAMAZAKI
;
Hidenao NORITAKE
;
Tetsuro SUZUKI
;
Takafumi SUDA
;
Yoshimasa KOBAYASHI
Author Information
- Publication Type:Original Article
- Keywords: Hepatitis C virus infection; Disturbed lipid metabolism; Apolipoproteins
- MeSH: Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins B; Apolipoproteins E; Cholesterol; Genotype; Hepacivirus*; Hepatitis C*; Hepatitis*; Humans; Lipid Metabolism; Lipoproteins; Recurrence
- From:Gut and Liver 2018;12(2):201-207
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Changes in lipid profiles in patients infected with hepatitis C virus (HCV) during direct-acting antiviral therapy have been reported in recent years. However, the clinical aspects of disturbed lipid metabolism in chronic HCV infection have not been fully elucidated. METHODS: Dynamic changes in serum total, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) cholesterol and apolipoprotein levels in patients infected with HCV genotype 1b were examined during combination therapy with daclatasvir (DCV) and asunaprevir (ASV). RESULTS: Total, LDL−, and HDL-cholesterol levels increased rapidly and persistently after week 4. Apolipoprotein (apo) A-I, apo B, apo C-II, and apo C-III levels were significantly higher at week 4 than at week 0. In contrast, apo A-II and apo E levels were significantly lower. The differences in LDL− and HDL-cholesterol levels were positively correlated with those of apo B and apo A-I, respectively. Interestingly, in patients with non-sustained virological response, these cholesterol levels decreased rapidly after viral breakthrough or viral relapse. Furthermore, similar changes were observed for apo A-I, apo B and apo C-III levels. CONCLUSIONS: Clearance of HCV using combination therapy with DCV and ASV results in rapid changes in serum lipid profiles, suggesting an influence of HCV infection on disturbed lipid metabolism.
